Conformal Medical Announces Leadership Expansion with Key Appointments

NASHUA, N.H. – February 4, 2025 – Conformal Medical, Inc., a medical device company developing next-generation left atrial appendage occlusion (LAAO) technology, today announced the appointment of Bruce Van Deman as Vice President of Clinical Affairs and Aurelio Valencia as Vice President of Operations. These strategic appointments reinforce the company's commitment to innovation and growth as it advances its mission to provide transformative solutions for stroke prevention in patients with atrial fibrillation.

"It's an exciting time to join Conformal Medical, and I look forward to the progress and outcomes of the CONFORM Pivotal Trial," said Van Deman. "The talented team here has developed something truly remarkable for patients. The innovative foam-based design of the CLAAS® AcuFORM™ system holds great potential to impact the field of LAAO therapy significantly."

Bruce Van Deman joins Conformal Medical with more than 25 years of medical device expertise in clinical research, strategic marketing, and medical sciences. He has a proven track record of advancing global clinical programs, developing integrated business strategies, and leading high-performing teams. Bruce previously served as the leader of Global Clinical Research and Medical Sciences for Medtronic Neurovascular and held senior leadership roles at NeoChord, Inc., Edwards Lifesciences, GOJO Industries, and Philips Healthcare. His leadership has delivered impactful clinical results in investigational and commercial settings worldwide.

"Having witnessed the devastating impact of stroke on loved ones, I am proud to contribute to a transformative therapy that has the potential to revolutionize stroke prevention," said Valencia. “As I lead the scale-up of our operations, I am committed to meeting the needs of patients and customers with products that set the standard for reliability, quality, and performance."

Aurelio Valencia brings over three decades of leadership in operations and manufacturing within the medical device industry. His extensive experience includes senior roles at companies such as Cutera, Inc., VENITI, Inc. (acquired by Boston Scientific), Medtronic Vascular, and Teleflex Medical/Hotspur Technologies. Throughout his career, Aurelio has consistently driven operational excellence, overseen complex manufacturing processes, and contributed to the strategic growth of startups and established organizations.

"We are delighted to welcome Bruce and Aurelio to the Conformal team," said James Reinstein, President and CEO of Conformal Medical. "Their combined expertise will be instrumental in scaling our operations and clinical initiatives, driving innovation, and delivering impactful solutions to patients and healthcare providers globally."

About Conformal Medical
Conformal Medical, Inc. is a medical device company developing devices to prevent stroke in patients with non-valvular atrial fibrillation. The company’s proprietary technology is intended to make left atrial appendage closure a same day, single operator procedure. For more information, visit https://conformalmedical.com/.

About Left Atrial Appendage Closure
More than six million people in the United States suffer from Afib, placing them at an increased risk of stroke.¹ Current standard of care for stroke prevention is chronic oral anticoagulants, which are not well accepted by patients due to concern about associated risk of bleeding. Left Atrial Appendage Occlusion (LAAO) is emerging as an important alternative to blood thinners for preventing strokes in patients with non-valvular Afib. First-generation LAAO devices are an estimated $1.4B global market in 2023 and are expected to grow to over $6B by 2030.^2,3

1. Kornej J, Börschel CS, Benjamin EJ, Schnabel RB. Epidemiology of Atrial Fibrillation in the 21st Century: Novel Methods and New Insights. Circ Res. 2020 Jun 19;127(1):4-20.
2. Piper Sandler Market Analyst Report, September 2023.
3. Boston Scientific Investor Update, September 2023.